Adjuvant PD-1 inhibitors enhance survival in high-risk HCC patients.

In a study involving 199 hepatocellular carcinoma patients, the use of adjuvant PD-1 inhibitors significantly improved both recurrence-free survival (RFS) and overall survival (OS) rates. After propensity score matching, 1-year RFS was 87.1% for those receiving PD-1 inhibitors versus 44.6% for non-recipients, while 1-year OS rates were 98.5% versus 90.7%, respectively. The findings suggest that PD-1 inhibitors may effectively mitigate tumor recurrence and enhance survival outcomes post-hepatectomy.